|
Match
|
Document |
Document Title |
|
|
7618949 |
Drug-eluting stents coated with P2Y12 receptor antagonist compound
The present invention provides a P2Y 12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y 12 receptor antagonist compounds or a pharmaceutically...
|
|
|
7612047 |
Degradation-resistant mononucleoside phosphate compounds
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that...
|
|
|
7608601 |
4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
The present invention relates to the use of nucleoside derivatives of formula I
wherein B signifies a 9-purinyl residue B1 of formula
or a 1-pyrimidyl residue B2 of formula...
|
|
|
7608600 |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention...
|
|
|
7608597 |
Methods and compositions for treating hepatitis C virus
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a...
|
|
|
7605143 |
2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
The invention provides compounds having the following general formula (I):
wherein X, R 1 , R 2 , R 7 and Z are as described herein.
|
|
|
7605137 |
Combination therapy comprising cloretazine
This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a...
|
|
|
7592445 |
Non-nucleotide composition and method for inhibiting platelet aggregation
This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation.
|
|
|
7592326 |
Method for stimulating the immune, inflammatory or neuroprotective response
Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune...
|
|
|
7589076 |
Substituted aryl piperidinylalkynyladenosines as A2AR agonists
A 2A agonists of formula (I) is provided, wherein R 1 , R 2 , R 4 , R 5 , X, Y, Z, n, p, and q are as described herein.
Also provided are compositions comprising and methods of using compounds...
|
|
|
7585850 |
Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases
The invention is directed to compositions and methods which permit the oral use of adenosine and adenosine phosphates for cardiovascular applications such as pulmonary artery hypertension, cardiac...
|
|
|
7582617 |
Myocardial perfusion imaging method
The present invention provides a method for using the partial adenosine A 2A receptor agonists having the following structure
in myocardiological perfusion imaging.
|
|
|
7576069 |
2-polycyclic propynyl adenosine analogs having A2A agonist activity
The invention provides compounds having the following general formula (I):
wherein X, R 1 , R 2 , R 7 and Z are as described herein.
|
|
|
7576068 |
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention...
|
|
|
7566703 |
Semi-soft C-class immunostimulatory oligonucleotides
The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for...
|
|
|
7563779 |
L-ergothioneine, milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage
This invention provides therapeutic compositions and combinations for the protection, treatment and repair of liver tissue. The invention relates to novel compositions and combinations comprising...
|
|
|
7557093 |
Composition for promoting collagen production
The invention provides a composition for promoting collagen production, and more specifically, provides a composition capable of promoting collagen production in human dermis. Further, the...
|
|
|
7557092 |
Purinergic modulation of smell
Disclosed are compositions and methods for modulating odor sensitivity, as well as screening methods for detecting compounds that modulate odor sensitivity.
|
|
|
7553823 |
C-pyrazole A2A receptor agonists
2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for...
|
|
|
7550442 |
Nucleoside analog inhibitors of reverse transcriptase
Compounds of formula (XXIII), or pharmaceutically acceptable salts or esters thereof, are inhibitors of reverse transcriptase:
R 4 is a nucleoside with Q substituting a 3′ hydroxyl group, and...
|
|
|
7521432 |
Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.
|
|
|
7517862 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7514417 |
A1 adenosine receptor agonists
Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists having the structure of Formula I:
which are useful for treating various disease states, in particular...
|
|
|
7504497 |
Orally bioavailable compounds and methods for inhibiting platelet aggregation
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or...
|
|
|
7479485 |
Method of treating arrhythmias
Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A 1 adenosine receptor...
|
|
|
7468357 |
Nucleosides with anti-hepatitis B virus activity
A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-nucleotide, optionally...
|
|
|
7465715 |
Method for treatment of multiple sclerosis
Individuals suffering from multiple sclerosis may be treated by administration of an A3 adenosine receptor agonist (A3RAg), such as APNEA, AB-MECA, IB-MECA or Cl-IB-MECA. The A3RAg is preferably...
|
|
|
7462604 |
Hair growth promotor composition
A hair growth promotor which is an ethanol or aqueous ethanol preparation comprising, as active ingredients for a hair growth promotor, (A) at least one compound selected from fatty acids having a...
|
|
|
7452870 |
Drug-eluting stents coated with P2Y12 receptor antagonist compound
The present invention provides a P2Y 12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y 12 receptor antagonist compounds or a pharmaceutically...
|
|
|
7435724 |
Degradation-resistant mononucleoside phosphate compounds
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that...
|
|
|
7427606 |
Method to reduce inflammatory response in transplanted tissue
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or...
|
|
|
7425546 |
Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such...
|
|
|
7423144 |
Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's...
|
|
|
7423025 |
L-nucleosides as ligands to adenosine receptors
Disclosed herein are compounds having Formula I, which are non-natural L-adenosine analogs. Also disclosed are their methods of making. Still further, disclosed are the uses of the disclosed...
|
|
|
7414036 |
Compounds useful as A3 adenosine receptor agonists
Adenosine analogue-type A3 receptor agonists having the formula
wherein
D is N or CH;
E is O;
X 1 is a group of the formula —CR 20 R 2 1 -CYCLE, where
R 20 and R 21 are the...
|
|
|
7399754 |
N2-quinoline or isoquinoline substituted purine derivatives
Novel compound having the following formula:
wherein W represents a hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 cycloalkyl, or an optionally substituted C...
|
|
|
7387796 |
Stable compositions of S-adenosyl-l-methionine with dextran
Stable compositions of S-adenosyl-1-methionine with dextran are described. The compositions according to the invention are stable over time and are valuable for use as active constituents in...
|
|
|
7381714 |
A1 adenosine receptor agonists
Disclosed are novel compounds that are partial and full A 1 adenosine receptor agonists having the structure of Formula I:
which are useful for treating various disease states, in particular...
|
|
|
7378401 |
Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5′-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the...
|
|
|
7378400 |
Method to reduce an inflammatory response from arthritis
The present invention provides a therapeutic method for treating an inflammatory response caused by autoimmune stimulation, comprising the administration to a patient in need thereof of an...
|
|
|
7368438 |
Non-nucleotide compositions and method for inhibiting platelet aggregation
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or...
|
|
|
7354907 |
Short immunomodulatory oligonucleotides
The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The...
|
|
|
7342003 |
Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
Provided is a method for the synthesis of an aralkyloxyadenosine or an alkoxyadenosine. The method includes protecting the hydroxyl sugar groups with a protecting group to produce a protected...
|
|
|
7335648 |
Non-nucleotide composition and method for inhibiting platelet aggregation
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or...
|
|
|
7335384 |
Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease...
|
|
|
7332479 |
Extracellular NAD+ and cADPR as potent anti-inflammatory agents
A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or...
|
|
|
7323453 |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
The present invention provides methods of inhibiting orthopoxvirus replication and/or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are...
|
|
|
7323452 |
Method for the accelerated in vivo removal of ethanol
A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as...
|
|
|
7323451 |
Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns,...
|
|
|
7319093 |
Antidiabetic 2-substituted-5′-O-(1-Boranotriphosphate) adenosine derivatives
2-Substituted-5′-O-(1-boranotriphosphate)adenosine derivatives having at position 2 a radical R1 selected from the group consisting of H; halogen; O-hydrocarbyl; S-hydrocarbyl; NR3R4; and...
|